Can't fact-check @cristina.noh's peptide claims without content

What did @cristina.noh actually say?

She described a three-peptide stack she calls the "glow peptide" -- GHK-Cu, BPC-157 (which she calls "APC 157"), and TB-500 -- framing it as a post-tummy-tuck healing protocol. She said the peptides come lyophilized (freeze-dried, crystallized) and need to be reconstituted before injection. She also directed viewers to a provider called "the face box" to get a customized peptide stack.

Let's be clear about what this video actually is: it's a recommendation to self-administer a multi-peptide injectable stack, sourced through a third party, based on a personal anecdote about cosmetic surgery recovery. That framing matters a lot for how we evaluate what follows.

Does the science back this up?

Partially -- but the gap between what the research actually shows and what this video implies is significant. GHK-Cu has real preclinical data behind it. BPC-157 has animal data. TB-500 (thymosin beta-4 fragment) has some human-adjacent research. None of these peptides are FDA-approved for the uses described.

GHK-Cu (copper peptide) has been studied for wound healing and skin remodeling with some legitimacy. Pickart and Margolina (2018, Cosmetics) documented its role in stimulating collagen synthesis and activating tissue remodeling genes. That's real. BPC-157, however, has robust data almost exclusively in rodents -- gastric ulcer healing, tendon repair, angiogenesis -- with essentially no completed randomized human trials as of 2024. TB-500, or its fragment Tβ4, has Phase II trial data for wound healing (Philp et al., 2004, Annals of the New York Academy of Sciences) but nothing close to approval for post-surgical cosmetic recovery. Stacking all three and calling it a "glow peptide" is a marketing construct, not a clinical protocol.

What did they get wrong (or right)?

She gets partial credit for the individual peptide descriptions. GHK-Cu does have anti-aging and wound-healing properties in the literature. TB-500 is associated with tissue regeneration in research settings. Calling BPC-157 anti-inflammatory and tissue-repair oriented is consistent with the animal data.

Where this goes sideways: she repeatedly mispronounces BPC-157 as "APC 157," which is a different designation entirely -- a small error that signals she may be working from secondhand information. More seriously, she's presenting a lyophilized injectable peptide stack sourced through a social media contact as a reasonable post-surgical recovery tool. Post-surgical tissue, especially after a tummy tuck, involves disrupted vasculature and active remodeling. Introducing unregulated injectables into that context -- without documented sterility testing, without physician oversight, and without any clinical indication -- is not a wellness optimization story. It's a real safety risk. The provider she recommends operates through DMs on Instagram, which is not how legitimate compounding or prescribing works.

What should you actually know?

These peptides are not approved by the FDA for injection in any of the contexts described. BPC-157 in particular was placed on the FDA's list of "bulk drug substances that present demonstrable difficulties" for compounding in 2023, meaning it cannot legally be compounded at most regulated pharmacies in the U.S. GHK-Cu topical preparations exist in cosmetics and are generally recognized as low-risk, but injectable GHK-Cu is a different story with different regulatory standing.

TB-500's active fragment (Tβ4) has been studied, but "TB-500" as sold through grey-market peptide vendors is not pharmaceutical-grade thymosin beta-4 -- potency, purity, and sterility are unverified without a certificate of analysis from an accredited third-party lab. Sourcing injectables through a social media DM referral, especially during surgical recovery, bypasses every layer of patient protection that exists for a reason. If you're interested in peptide therapy, a licensed provider who prescribes through a licensed 503B outsourcing facility or compounding pharmacy is the baseline minimum.